Skip to main content

Table 2 Clinical characteristics of patients with NMOSD and MS in relapse phase

From: Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder

 

NMOSD (n = 26)

MS (n = 18)

Disease duration, months (range)

42.7 (0–240)

62.4 (0–204)

Period from the acute relapse to CSF sampling, days (range)

14 (1–30)

19.2 (1–60)

Location of lesion

 Spinal cord (%)

23 (88.4)

5 (27.7)

 Brain (%)

2 (7.6)

14 (77.7)

 Optic nerve (%)

2 (7.6)

2 (11.1)

Length of spinal cord involvement, number of segments (range)

5.8 (2–17)

1.4 (1–2)

Treatment at CSF sampling (%)

7 (26.9)

11 (61.1)

 Prednisolone

6 (23.0)

 Immunosuppressants

4 (15.3)

 Interferon-β

7 (38.8)

 Fingolimod

3 (16.6)

 Dimethyl fumarate

1 (5.5)

  1. NMOSD neuromyelitis optica spectrum disorder, MS multiple sclerosis, CSF cerebrospinal fluid